Simulations of the popPK model, following various AOM dosing regimens (including oral initiation and coadministration of CYP2D6 or CYP3A4 inhibitors) for subjects classified with poor or extensive CYP2D6 metabolism, allowed for guidance of dosing recommendations. This evidence concerns the gene CYP2D6 and infectious otitis media.